Hikma Pharma launches Xyrem’s generic in US
The company will have 180 days of marketing exclusivity for its authorised generic product in the US
Hikma Pharma has launched an authorised generic version of Jazz Pharma’s Xyrem (sodium oxybate) oral solution CIII. The company will have 180 days of marketing exclusivity for its authorised generic product in the US, according to a statement from Hikma Pharma.
Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat the following symptoms in people seven years of age or older with narcolepsy, the statement said.
It further mentioned that Jazz Pharma reported net sales for Xyrem of $1.3 billion in 2021.
- Advertisement -
thanks for sharing for all info!